Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 64Neoplasms 7Neoplasms, Plasma Cell 6Recurrence 5Hematologic Neoplasms 4Renal Insufficiency 3Paraproteinemias 3Lymphoma 3Immunoglobulin Light-chain Amyloidosis 3Hematologic Diseases 3Smoldering Multiple Myeloma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms by Histologic Type 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Leukemia 2Blood Protein Disorders 2Purpura 1Prostatic Neoplasms 1Neoplasm, Residual 1Nausea 1Natural Killer/T-cell Lymphoma 1Monoclonal Gammopathy of Undetermined Significance 1Macroglossia 1Lymphoproliferative Disorders 1Lymphoma, Large B-Cell, Diffuse 1Lymphadenopathy 1Leukemia, Plasma Cell 1Immunoproliferative Disorders 1

Interventions

Lenalidomide 17Dexamethasone 15Calcium Dobesilate 8daratumumab 5dexamethasone acetate 4dexamethasone 21-phosphate 4carfilzomib 4auricularum 4Melphalan 4Leflunomide 3Curcumin 3isatuximab 2iberdomide 2elotuzumab 2Peripheral Blood Stem Cell Transplantation 2PVX-410 vaccine 2Denosumab 2Cyclophosphamide 2Bortezomib 2siltuximab 1selinexor 1sargramostim 1pomalidomide 1poly ICLC 1piperine 1pembrolizumab 1ixazomib 1ibrutinib 1fludarabine phosphate 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × isatuximab × Clear all
NCT02960555 2026-04-15

Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
61 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT06762769 2025-08-01

MODIFY

University College, London

Phase 2 Recruiting
63 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡